Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Hu on the Next Steps for Biopsies in Prostate Cancer

August 30th 2017

Jim Hu, MD, MPH, director of the LeFrak Center for Robotic Surgery at Weill Cornell Medicine/NewYork-Presbyterian Hospital and the Ronald Lynch Chair of Urologic Oncology at Weill Cornell Medical College, discusses the next steps of biopsies for patients with prostate cancer.

Dr. Loeb on the Results of Active Surveillance for Prostate Cancer

August 29th 2017

Stacy Loeb, MD, assistant professor of urology and population health at NYU Langone School of Medicine, discusses the results and impact of active surveillance on patients with prostate cancer.

Dr. Sartor on Conclusions and Future of Sipuleucel-T in Prostate Cancer

August 28th 2017

Oliver Sartor, MD, medical oncologist at Tulane University School of Medicine, discusses conclusions drawn from an analysis of African-American patients receiving sipuleucel-T (Provenge) in metastatic castration-resistant prostate cancer and the potential for combinations with this agent.

Reduced-Dose Cabazitaxel Shows Efficacy in mCRPC

August 25th 2017

Results from the PROSELICA trial showed that 20 mg/m2 of cabazitaxel (Jevtana) was as safe and effective as the 25 mg/m2 dose for postdocetaxel patients with metastatic castration-resistant prostate cancer.

Dr. Feldman Discusses Metabolomic Findings in Prostate Cancer

August 23rd 2017

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses metabolomic findings in prostate cancer.

Dr. Higano on Changes Being Made in the Field of Prostate Cancer

August 22nd 2017

Celestia Higano, MD, professor of medicine and urology at the University of Washington, and a member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, discusses the changes being made in the field of prostate cancer.

Dr. Choyke Discusses the Challenges With MRI in Prostate Cancer

August 21st 2017

Peter Choyke, MD, FACR, chief of Molecular Imaging Program, National Cancer Institute, discusses the challenges with MRI in prostate cancer.

Dr. Stephenson on the Development of Biomarkers for Prostate Cancer

August 21st 2017

Andrew J. Stephenson, MD, director for the Center of Urologic Oncology at the Cleveland Clinic, discusses the development of biomarkers for patients with prostate cancer.

AR-V7 Biomarker Test Remains on the Wish List for CRPC

August 20th 2017

The use of biomarkers in genitourinary cancers offers exciting potential in understanding which patients may do better with androgen-targeting therapies.

Dr. Higano on Combinations With Radium-223 for Prostate Cancer

August 18th 2017

Celestia Higano, MD, professor of medicine and urology at the University of Washington, and a member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, discusses risks associated with combining radium-223 dichloride (Xofigo) for patients with prostate cancer.

Drake Discusses Immunomodulatory Therapies

August 18th 2017

Charles Drake, MD, PhD, shares his insight on the promise and challenges with immunomodulatory drugs, and immune-activating agents in prostate cancer.

Dr. Feldman on Remaining Challenges With Biomarkers in Prostate Cancer

August 18th 2017

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses the remaining challenges with biomarkers in prostate cancer.

Dr. Sartor on the Science of Sipuleucel-T for Prostate Cancer

August 18th 2017

Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the science behind the results of a study investigating sipuleucel-T (Provenge) for patients with castration-resistant prostate cancer (CRPC).

Dr. Slovin on Approaches of Immunotherapy in Prostate Cancer

August 17th 2017

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses approaches of immunotherapy for patients with prostate cancer.

Dr. Brawer on the Significance of the Prolaris Genetic Test for Prostate

August 17th 2017

Michael Brawer, MD, vice president of medical affairs, Myriad Genetic Laboratories, discusses the significance of the Prolaris genetic test in predicting prostate cancer aggressiveness in African-American men.

Testing Picture Is Coming Into Sharper Focus for Familial and Hereditary Prostate Cancer

August 16th 2017

Research into the biology of prostate cancer has resulted in a growing understanding of the molecular drivers of the malignancy, resulting in a rapid evolution of genetic testing that is poised to revolutionize the diagnosis and care of at-risk men as well as those who have the disease.

Dr. Choyke Discusses Screening in Prostate Cancer

August 16th 2017

Peter Choyke, MD, FACR, chief of the Molecular Imaging Program, National Cancer Institute, discusses screening in prostate cancer.

Dr. Choyke on Developments for the Screening of Prostate Cancer

August 15th 2017

Peter Choyke, MD, FACR, chief of Molecular Imagine Program, National Cancer Institute, discusses developments being made in screening for patients with prostate cancer.

Loeb Discusses Genomic Testing and Accurate Prostate Cancer Staging

August 11th 2017

Stacy Loeb, MD, discusses the promise and challenges with genomic testing in prostate cancer.

The Clinical Value of MRI Testing in Prostate Cancer

August 11th 2017

Andrew Vickers, PhD, attending research methodologist at Memorial Sloan Kettering Cancer Center, discusses the clinical value of MRI testing in prostate cancer.